Aim: Adiponectin is a key molecule involved in metabolic syndrome. Single nucleotide polymorphisms (SNPs) in the ADIPOQ gene encoding adiponectin correlate with various diseases, such as diabetes mellitus; however, there is insufficient information about ADIPOQ SNPs and the onset of cardiovascular events. Methods: This hospital-based cohort study included 353 patients with essential hypertension (mean age, 62.9±0.6; mean follow-up period. 7.9±0.2 years) in whom ADIPOQ SNPs encoding G276T, I164T, A349G, and/or G967A amino acid changes were detected. We analyzed the correlation between ADIPOQ SNPs and various parameters, including pulse wave velocity (PWV), and assessed whether these SNPs could be risk factors for the onset of stroke, cardiovascular disease, and mortality. Results: Subjects with the T allele of G276T showed significantly lower HDL cholesterol, and significantly higher HbA1c and brachial-ankle PWV (baPWV). Kaplan-Meier analysis revealed that subjects with the T allele of G276T had a significantly higher frequency of stroke (p= 0.0489). The Cox proportional hazard model showed that the T allele of G276T was an independent and significant risk factor for stroke after adjusting for traditional risk factors (relative risk: 1.879, p = 0.0479); however, when adjusted for traditional risk factors and baPWV, the relative risk was significantly diminished (relative risk: 0.710, p=0.4937). G276T was significantly correlated with dyslipidemia and glucose metabolism. Conclusion: The T allele of G276T was a significant and independent risk for the onset of stroke, and mediated the incidence of stroke through increased arterial stiffness. J Atheroscler Thromb, 2013; 20:152-160.
Introduction
Adiponectin is an adipose tissue-specific protein well known as one of the key molecules involved in metabolic syndrome, having anti-inflammatory and anti-atherogenic effects 1) . Several reports have shown that adiponectin was significantly correlated with glu-cose metabolism 2) , lipid metabolism 3) , oxidative stress 4) , and insulin resistance 5) . In addition, previous studies reported that decreased adiponectin was associated with various diseases, such as type 2 diabetes mellitus 6) , obesity 7) , hypertension 8, 9) , left ventricular diastolic dysfunction 10) , and coronary artery diseases [11] [12] [13] . Various studies have also suggested a correlation between hypoadiponectinemia and atherosclerotic changes or vascular properties. For example, low serum adiponectin levels were reported to be associated with increased intima-media thickness 14) . We previously reported that hypoadiponectinemia is associated with impaired endothelium-dependent vasorelaxation and that the measurement of plasma adiponectin January 1998 and June 2004 at Osaka University Medical Hospital.
The ADIPOQ SNPs encoding G276T (rs1501299), I164T (rs185847354), A349G (rs2241767), and G967A (rs3774262) amino acid changes were detected in 353 serial outpatients who had blood drawn for genotype testing. Patients who had atrial fibrillation or malignant diseases were excluded from the study. The study protocol was approved by the hospital ethics committee, and written informed consent was obtained from all participants. Since the present study is a prospective cohort study dealing with SNPs we did not perform a genetic power calculation but a normal power calculation to evaluate the sufficiency of our sample size to detect the difference between subjects with and without risk alleles after study completion, and it showed the sufficiency of our sample size.
Follow-Up Evaluation
We conducted clinical follow-up by clinical visits, mailed questionnaires, and telephone contact every September from 2003. The questionnaire included events related to hypertensive complications and cause of death. We also confirmed each patient's responses levels might be a marker of endothelial dysfunction 15) . Meanwhile, the correlation between adiponectin and pulse wave velocity (PWV), which represents arterial stiffness, is still controversial. Some studies reported that there were no correlations between adiponectin and PWV 16) . On the other hand, several reports indicated that PWV was significantly correlated with serum adiponectin levels 17, 18) or serum high molecular weight adiponectin 19) . Another study reported that plasma adiponectin levels are associated with the progression of arterial stiffness, as evaluated by PWV in hypertensive patients 20) . Adiponectin is encoded by the ADIPOQ gene, located on chromosome 3q27 in a region previously shown to have genetic linkage with type 2 diabetes mellitus 21) . Many studies have investigated several single nucleotide polymorphisms (SNPs) in various ethnic groups. The ADIPOQ SNP G276T in intron 2 is the most widely known and studied SNP. Previous reports indicated that G276T was significantly correlated with type 2 diabetes mellitus 22) , insulin resistance 23) , coronary artery disease 24) , proteinuria and hypertension 25) , and so on. The ADIPOQ SNP I164T mutation in exon 3 is also well studied and reported to be correlated with type 2 diabetes mellitus 5) , metabolic syndrome, and coronary artery disease 26) . These SNPs were also correlated with serum adiponectin levels 27, 28) ; however, it should be noted that several studies reported that they could not find a significant correlation between ADIPOQ SNPs and type 2 diabetes mellitus even in the same ethnic group 29, 30) . In addition, although many studies established evidence that serum adiponectin levels are significantly correlated with cardiovascular events, information about ADI-POQ SNPs and the onset of cardiovascular events and total mortality is insufficient, and is investigated in this cohort study.
In this study, we analyzed the effect of ADIPOQ SNPs upon various parameters, including PWV. Then we assessed the hypothesis that subjects with risk alleles of ADIPOQ SNPs showed significantly higher incidences of cardiovascular events, and investigated how ADIPOQ SNPs influence the onset of cardiovascular events.
Methods

Study Subjects and Study Design
This hospital-based cohort study was designed as part of the Non-invasive Atherosclerotic Evaluation in Hypertension (NOAH) study 31) in which 813 serial Japanese outpatients, who had been diagnosed with essential hypertension, were sequentially recruited between ers with an electronic sphygmomanometer (HEM-705IT or HEM-711; OMRON (Kyoto, Japan). Following the guidelines for the management of hypertension, clinical blood pressure was measured twice while the patient was in a sitting position after a 5-min rest, and the average of two readings was used as the office blood pressure if the difference in measured values was less than 5 mmHg. When the difference in measured values was more than 5 mmHg, additional measurements were conducted to obtain stable blood pressure readings and the average of two stable readings was used as the office blood pressure.
Genotyping
Total genomic DNA was extracted from leukocytes obtained from samples of whole blood, following standard techniques. In this study, the TaqMan PCR assay, described previously, was used to perform the polymorphism analysis 9) . ADIPOQ polymorphisms encoding the G276T, I164T, A349G, and G967A amino acid substitutions were determined by amplification with biotinylated primers and hybridization to immobilized sequence-specific oligonucleotides as previously described 9) .
Pulse Wave Velocity Measurement
We evaluated brachial-ankle PWV (baPWV) as a representative PWV to evaluate arterial stiffness. For PWV measurements, participants visited the hospital in the morning; they were instructed not to take any antihypertensive drugs, nitrates, or aspirin for the 8 hours preceding their visit. Measurements were performed in the morning while each patient was in a supine position after a 30-min rest period. baPWV measurements were performed in a controlled environment at 22±2 ℃. Three measurements, taken 2 minutes apart, were averaged.
Electrocardiogram, bilateral brachial and ankle blood pressures, and carotid and femoral arterial pulse waves were simultaneously measured with a vascular testing device (VP-2000; Omron Healthcare, Japan) 32) .
Since the values of baPWV obtained on the right and left sides were identical (r = 0.83, p＜0.0001), we used only the right baPWV in the present study. A previous in detail by checking them against their medical records. The primary endpoint of this study was new onset of stroke (paralysis and diagnosis with computed tomography and/or magnetic resource imaging) and new onset of cardiovascular disease (CVD), including angina pectoris (typical chest pain with ST segment changes on electrocardiograms), myocardial infarction (ST segmental elevation with a more than twofold elevation of creatinine kinase), heart failure (diagnosed using American Heart Association criteria), and rupture of an aortic aneurysm (diagnosed with ultrasound echography or computed tomography). The follow-up duration was considered to encompass the interval from the initial evaluation to the time of event onset or September 2010. The average follow-up period was 7.9±0.2 years.
BP Measurements
Conventional BP was measured by trained observ- of patients in this study. The mean age of the 353 subjects was 62.9±0.6 years. We identified ADIPOQ SNPs as follows: G276T (GG = 171, GT = 147, TT = 35), I164T (TT = 350, T C = 3), A349G (AA = 192, AG = 130, GG = 31), and G967A (GG = 192, GA = 128, AA = 33). Table 2 shows the genotyping results. The genotype frequencies were in Hardy-Weinberg equilibrium (p = 0.6798, 0.9361, 0.1885, 0.0901, respectively). Since A349G and G967A showed very strong linkage disequilibrium, and there were very few subjects (n = 3) with the C allele in I164T, we only analyzed the impact of ADIPOQ G276T and A349G on systemic atherosclerotic changes and prognosis. Fig. 1 shows the linkage disequilibrium structure. During the mean follow-up period of 7.9±0.2 years, 42 strokes, 23 cardiovascular diseases, 70 strokes plus cardiovascular disease, and 39 deaths were recorded.
First, we compared the characteristics of subjects without risk alleles (G276T: T allele, and A349G: G allele) with subjects with the two polymorphism risk alleles, respectively. Subjects with the T allele of the G276T SNP had significantly lower HDL cholesterol (55.2±1.2 mg/dL vs. 58.2±1.3 mg/dL, p = 0.0417), significantly higher HbA1c (5.7±0.1 % vs. 5.4±0.1%, study reported that this automatic noninvasive device is accurate and requires minimal technical skill, and established the validity and reliability of these devices for measuring PWV 33) .
Statistical Analysis
Data were analyzed using JMP ver. 9.0.1 (SAS, Cary, NC, USA), and are presented as the mean± standard error measurement (SEM). An event-free curve was estimated employing the Kaplan-Meier method. The log-rank test was used to compare the differences in event-free rates between subjects. The results in subjects with risk alleles were compared with those in subjects without risk alleles. The Cox proportional hazard model was used to detect the relative risks of ADIOQ SNPs on the prognoses. Analysis of variance and Student's t -test were used to test for significant differences between patients with higher and lower variability in SBP. A value of p＜0.05 was regarded as significant. Table 1 shows the baseline clinical characteristics CVD (p = 0.1989), stroke and CVD (p = 0.0979), and total mortality (p = 0.8688), although there was a nonsignificant trend for subjects with the T allele to have a worse prognosis. Similarly, Fig. 3 shows the correlation between the ADIPOQ A349G mutation and prognosis. Kaplan-Meier analysis showed no significant differences between subjects with and without the G allele in the frequency of stroke (p = 0.4241), CVD (p = 0.5229), stroke and CVD (p = 0.6040), and total mortality (p = 0.3543).
Results
Next, we used a Cox proportional hazard model to assess whether ADIPOQ G276T could predict the onset of stroke independent of other risk factors. In model 1 (unadjusted), the G276T T allele was a significant risk factor for stroke (relative risk: 1.885, p = 0.0464). In model 2, which was adjusted for age, sex, with or without diabetes mellitus, and with or without dyslipidemia, since subjects with the T allele of the G276T SNP had significantly lower HDL cholesterol and significantly higher HbA1c (Table 3) , the G276T T allele remained an independent and significant risk p=0.0230), and significantly higher baPWV (1740.9± 39.5 vs. 1636.8±40.6, p = 0.0341). There were no significant differences in baseline characteristics between subjects with and without the G allele of the A349G SNP ( Table 3) . After adjustment for age and sex, subjects with the T allele showed a non-significant lower trend of HDL cholesterol (p = 0.0780) and non-significant higher trend of HbA1c (p= 0.0558) respectively. We analyzed serum adiponectin levels in 304 of the 353 subjects. There were no significant differences in serum adiponectin levels between subjects without or with the T allele of G276T (GG: 7.61±0.40 vs. GT ＋TT: 7.76±0.41, p = 0.7940) and between subjects without or with the G allele of the A349G mutation (AA: 7.49±0.37 vs. AG＋GG: 7.92±0.44, p=0.4487). Fig. 2 shows the correlation between ADIPOQ G276T and prognosis. Kaplan-Meier analysis showed that subjects with the T allele had a higher frequency of stroke (p = 0.0489). On the other hand, there were no significant differences between subjects with and without the T allele with regards to the frequency of Fig. 2 . Kaplan-Meier analysis of cardiovascular events and mortality between subjects with and without the T allele of ADIPOQ G276T. Subjects with the T allele had a significantly higher incidence of stroke; however, there were no significant difference in the incidence of CVD, stroke plus CVD, and total mortality. tus, with or without dyslipidemia (adjusted in model 2) and the smoking index, the relative risk also diminished (relative risk: 1.818, p = 0.0634).
Discussion
Since there has been a discrepancy in the results of previous studies reporting a correlation between the ADIPOQ G276T mutation and diabetes mellitus 22, 29) , the first important finding of this study was that in Japanese essential hypertensives, subjects with the T allele of ADIPOQ G276T had lower HDL cholesterol and higher HbA1c levels. Although adiponectin was related to various metabolic disorders and hypertension 8, 9) , we believe that the disease uniformity of the subjects in our cohort, who were essential hypertensives, could partially exclude the influence of potential confounders. Moreover, we showed for the first time that subjects with the T allele of ADIPOQ G276T have significantly higher PWV. PWV is widely recognized as an index of arterial stiffness and many studies factor for stroke (relative risk: 1.879, p = 0.0479). However, in model 3, which was adjusted for age, sex, with or without diabetes mellitus, with or without dyslipidemia (adjusted in model 2) and baPWV, the relative risk was significantly diminished (relative risk: 0.710, p = 0.4937) ( Table 4) . Next, in model 4, which was adjusted for age, sex, smoking index (defined as the number of cigarette-years smoked), and SBP, which are widely recognized as traditional risk factors for stroke, the G276T T allele showed a non-significant trend for higher risk for stroke (relative risk: 1.784, p = 0.0746), and additional adjustment for baPWV similarly diminished the relative risk (relative risk: 0.711, p = 0.4895) ( Table 5 ). Finally, we used similar models to investigate the statistical impact of SBP and the smoking index. In model 6, which was adjusted for age, sex, with or without diabetes mellitus, with or without dyslipidemia (adjusted in model 2) and SBP, the relative risk was diminished (relative risk: 1.761, p = 0.0812), and in model 7, which was adjusted for age, sex, with or without diabetes melli- Fig. 3 . Kaplan-Meier analysis of cardiovascular events and mortality between subjects with and without the G allele of ADIPOQ A349G. There were no significant differences in the incidence of stroke, CVD, stroke plus CVD, and total mortality. changes in arterial stiffness, not through increased serum adiponectin levels. To our knowledge, this is the first cohort study to show the impact of ADIPOQ G276T on prognoses and to suggest a mechanism of how ADIPOQ G276T affects the onset of stroke. Previous studies reported the correlation between PWV and silent cerebrovascular diseases 38) or insulin resistance 39) , and our results supported and provided new insight into these correlations.
There are several limitations of the present study. First, this was a hospital-based cohort study and the study population was relatively small; larger cohort studies and multi-center trials are therefore needed to avoid study bias. Second, since this study was conducted at a university hospital, many study subjects had taken various oral drugs at the time of enrollment, such as angiotensin receptor type Ⅱ blockers, angiotensin converting enzyme inhibitors, and statins; these medications might contribute to better outcomes. Third, since very few subjects (n=23) developed CVD, we found a non-significant trend for subjects with the T allele of the ADIPOQ G276T to have a higher frequency of CVD. Similarly, since only a few subjects suffered CVD, stroke and death, we could not adjust for all risk factors in one model when we analyzed our subjects using the Cox proportional hazard model. Moreover, in model 7, which was adjusted for the smoking index in addition to age, sex, with or without diabetes mellitus and with or without dyslipidemia, the relative risk of ADIPOQ SNP for the incidence of stroke was diminished, so it could not be completely ruled out that our results included an alpha error caused by smoking as a confounding bias; therefore, have reported a correlation between PWV and cardiovascular events 31, [34] [35] [36] . The present result indicates that subjects with the T allele of ADIPOQ G276T could have increased arterial stiffness. Meanwhile, there was no significant correlation between ADIPOQ A349G and metabolic parameters or PWV.
Another important finding of the present study was that subjects with the T allele of ADIPOQ G276T had a significantly higher frequency of stroke, independent of risk factors such as age, sex, diabetes mellitus, and dyslipidemia, and that subjects with this allele also had a non-significant trend for a higher incidence of stroke after traditional risk factors (age, sex, smoking, and SBP). Despite the significant difference in the onset of stroke, we showed no difference in serum adiponectin levels between subjects with or without the T allele of ADIPOQ G276T. Previously, serum adiponectin levels were reported as not being independently associated with stroke or brain infarction 37) . These results suggested that there were other mechanisms by which ADIPOQ G276T affects the incidence of stroke. In addition, we showed that SBP and the smoking index (especially SBP) have an impact on the correlation between ADIPOQ G276T and the incidence of stroke in model 6 and model 7.
In the present study, the Cox proportional hazard model showed that the relative risk of having the T allele of ADIPOQ G276T was significantly diminished after adjusting for several risk factors and baPWV. This novel finding suggests that ADIPOQ G276T mediates the incidence of stroke through larger multicenter trials are needed to investigate the impact of ADIPOQ SNPs on CVD and other events related to atherosclerotic changes more precisely.
In conclusion, we show that ADIPOQ G276T is significantly correlated with dyslipidemia and glucose metabolism. We also show that the T allele of ADI-POQ G276T is a significant and independent risk factor for the onset of stroke and mediates the incidence of stroke through an increase in arterial stiffness.
